Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial.

Autor: Akrami M; Cardiovascular Department, Shiraz University of Medical Sciences, Shiraz, Iran., Izadpanah P; Cardiovascular Department, Shiraz University of Medical Sciences, Shiraz, Iran., Bazrafshan M; Cardiovascular Department, Shiraz University of Medical Sciences, Shiraz, Iran., Hatamipour U; Cardiovascular Department, Shiraz University of Medical Sciences, Shiraz, Iran., Nouraein N; Cardiovascular Department, Shiraz University of Medical Sciences, Shiraz, Iran., Drissi HB; Cardiovascular Department, Shiraz University of Medical Sciences, Shiraz, Iran. hamedbazrafshan@yahoo.com., Manafi A; Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Jazyk: angličtina
Zdroj: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2021 Dec 07; Vol. 21 (1), pp. 583. Date of Electronic Publication: 2021 Dec 07.
DOI: 10.1186/s12872-021-02393-9
Abstrakt: Background: Cardiovascular disease in particular acute coronary syndrome (ACS) is remained one of the most cause of morbidity and mortality, annually. Considering inflammatory pathway of atherosclerosis, colchicine as an anti-inflammatory drug is introduced to be effective in pathogenesis, prognosis and mortality rate of these patients. So in order to find out the effects of this drug we conducted this trial to know whether it reduces major adverse cardiac events (MACE) in ACS patients or not.
Methods: In a prospective randomized double-blinded placebo-controlled trial, we enrolled ACS patients (40-70 years) with recent ST-segment elevation myocardial infarction (STEMI) or NSTE-ACS diagnosed by coronary angiography and managed with either medical therapy or percutaneous coronary intervention. Patients were assigned to two groups either receiving colchicine 0.5 mg daily or placebo for 6 months. Both groups simultaneously received standard medical therapy as accessible guidelines. MACE occurrence consists of decompensated heart failure, ACS, stroke and survival rate compared between two groups.
Results: A total of 249 patients were recruited between October 2019-March 2020 with mean age of 56.89 ± 7.54, 69.5% males; 120 assigned to the colchicine group and 129 assigned to the placebo group. Over the 6 months' period, 36 MACE occurred that were 8 events in the colchicine group compared with 28 events in the placebo group experiencing the event (P = 0.001). All of four deaths in the colchicine group and two in the placebo group were due to cardiovascular events. Evaluating adverse effects, gastrointestinal symptom was the most with the rate of 15 (12.5%) in the colchicine group and 3 (2.5%) in the controls. (P = 0.002).
Conclusion: The addition of colchicine to standard medical therapy in ACS patients significantly reduces MACE occurrence and improves survival rate over the time.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: